Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.

Hayashida T, Jinno H, Mori K, Sato H, Matsui A, Sakurai T, Hattori H, Takayama S, Wada M, Takahashi M, Seki H, Seki T, Nagayama A, Matsumoto A, Kitagawa Y

Open source

DOI: 10.1186/s12885-018-4628-7
Published: 2018 Jun 28
Container: BMC cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12885-018-4628-7,
  title = {Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.},
  author = {Hayashida T and Jinno H and Mori K and Sato H and Matsui A and Sakurai T and Hattori H and Takayama S and Wada M and Takahashi M and Seki H and Seki T and Nagayama A and Matsumoto A and Kitagawa Y},
  year = {2018},
  journal = {BMC cancer},
  doi = {10.1186/s12885-018-4628-7},
  url = {https://doi.org/10.1186/s12885-018-4628-7}
}

RIS

TY  - JOUR
TI  - Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
AU  - Hayashida T
AU  - Jinno H
AU  - Mori K
AU  - Sato H
AU  - Matsui A
AU  - Sakurai T
AU  - Hattori H
AU  - Takayama S
AU  - Wada M
AU  - Takahashi M
AU  - Seki H
AU  - Seki T
AU  - Nagayama A
AU  - Matsumoto A
AU  - Kitagawa Y
PY  - 2018
JO  - BMC cancer
DO  - 10.1186/s12885-018-4628-7
UR  - https://doi.org/10.1186/s12885-018-4628-7
ER  -

APA

T, H., H, J., K, M., H, S., A, M., T, S., H, H., S, T., M, W., M, T., H, S., T, S., A, N., A, M., & Y, K. (2018). Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.. BMC cancer. https://doi.org/10.1186/s12885-018-4628-7

Source records

pubmed · retrieved 2026-09-26T15:44:07.919Z